文献速递心脑血管急症重症综合管理与镇静镇痛

近期使用非维生素K拮抗剂口服抗凝药与接受阿替普酶治疗的急性缺血性卒中患者颅内出血的相关性

Association of Recent Use of Non-Vitamin K Antagonist Oral Anticoagulants With Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Treated With Alteplase.
PubMed 文献 · JAMA · 2022-01-01
一句话结论急性缺血性卒中接受静脉阿替普酶治疗者,若病前7天内使用过NOAC,校正后症状性颅内出血风险未显著增加(校正OR 0.88,95%CI 0.70-1.10)。

该回顾性队列研究纳入2015年4月至2020年3月美国1752家医院Get With The Guidelines-Stroke项目中163 038例在症状发作4.5小时内接受静脉阿替普酶治疗的急性缺血性卒中患者,其中2207例(1.4%)病前7天内使用NOAC,160 831例(98.6%)未使用抗凝药。主要终点为阿替普酶给药后36小时内症状性颅内出血,NOAC组未校正发生率3.7% vs 未抗凝组3.2%,校正后风险无显著差异(校正OR 0.88,95%CI 0.70-1.10;校正RD -0.51%,95%CI -1.36%至0.34%)。住院死亡率等次要安全终点无显著差异;7项次要功能结局中4项校正后有利于NOAC组,包括出院回家比例45.9% vs 53.6%(校正OR 1.17,95%CI 1.06-1.29;校正RD 3.84%,95%CI 1.46%至6.22%)。作者结论认为,病前7天内使用NOAC与未使用抗凝药相比,未显著增加颅内出血风险。

要点

  • 急性缺血性卒中4.5小时内接受静脉阿替普酶者,病前7天内使用NOAC(2207例)与未抗凝(160 831例)相比,校正后症状性颅内出血风险无显著差异(校正OR 0.88,95%CI 0.70-1.10)。
  • NOAC组患者更年长(中位75岁 vs 70岁)、心血管合并症更多、卒中更重(中位NIHSS 10 vs 7),标准化差异均>10。
  • 住院死亡率NOAC组6.3% vs 未抗凝组4.9%,校正后无显著差异(校正OR 0.84,95%CI 0.69-1.01)。
  • 7项次要功能结局中4项校正后有利于NOAC组,出院回家比例45.9% vs 53.6%(校正OR 1.17,95%CI 1.06-1.29)。

适用人群与场景

  • 急性缺血性卒中在症状发作4.5小时内接受静脉阿替普酶治疗、病前7天内使用NOAC或未使用长期抗凝药的患者。
  • 数据来自2015年4月至2020年3月美国1752家参与Get With The Guidelines-Stroke项目的医院,并补充Addressing Real-world Anticoagulant Management Issues in Stroke登记数据。

研究设计与关键结果

  • 回顾性队列研究,纳入163 038例接受静脉阿替普酶治疗的急性缺血性卒中患者(中位年龄70岁,IQR 59-81;女性49.1%),其中2207例(1.4%)病前7天内使用NOAC,160 831例(98.6%)未使用抗凝药。
  • NOAC组与未抗凝组比较:中位年龄75岁(IQR 64-82) vs 70岁(IQR 58-81);中位NIHSS评分10(IQR 5-17) vs 7(IQR 4-14);标准化差异均>10。
  • 主要终点症状性颅内出血(阿替普酶后36小时内):NOAC组未校正发生率3.7%(95%CI 2.9%-4.5%) vs 未抗凝组3.2%(95%CI 3.1%-3.3%);校正OR 0.88(95%CI 0.70-1.10),校正RD -0.51%(95%CI -1.36%至0.34%)。
  • 次要安全终点住院死亡率:NOAC组6.3% vs 未抗凝组4.9%;校正OR 0.84(95%CI 0.69-1.01),校正RD -1.20%(95%CI -2.39%至-0%)。
  • 7项次要功能结局中4项校正后有利于NOAC组,包括出院回家比例45.9% vs 未抗凝组53.6%(校正OR 1.17,95%CI 1.06-1.29;校正RD 3.84%,95%CI 1.46%至6.22%)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,在接受静脉阿替普酶治疗的急性缺血性卒中患者中,病前7天内使用NOAC与未使用抗凝药相比,未与颅内出血风险显著增加相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Current guidelines recommend against use of intravenous alteplase in patients with acute ischemic stroke who are taking non-vitamin K antagonist oral anticoagulants (NOACs).

OBJECTIVE: To evaluate the safety and functional outcomes of intravenous alteplase among patients who were taking NOACs prior to stroke and compare outcomes with patients who were not taking long-term anticoagulants.

DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study of 163 038 patients with acute ischemic stroke either taking NOACs or not taking anticoagulants prior to stroke and treated with intravenous alteplase within 4.5 hours of symptom onset at 1752 US hospitals participating in the Get With The Guidelines-Stroke program between April 2015 and March 2020, with complementary data from the Addressing Real-world Anticoagulant Management Issues in Stroke registry.

EXPOSURES: Prestroke treatment with NOACs within 7 days prior to alteplase treatment.

MAIN OUTCOMES AND MEASURES: The primary outcome was symptomatic intracranial hemorrhage occurring within 36 hours after intravenous alteplase administration. There were 4 secondary safety outcomes, including inpatient mortality, and 7 secondary functional outcomes assessed at hospital discharge, including the proportion of patients discharged home.

RESULTS: Of 163 038 patients treated with intravenous alteplase (median age, 70 [IQR, 59 to 81] years; 49.1% women), 2207 (1.4%) were taking NOACs and 160 831 (98.6%) were not taking anticoagulants prior to their stroke. Patients taking NOACs were older (median age, 75 [IQR, 64 to 82] years vs 70 [IQR, 58 to 81] years for those not taking anticoagulants), had a higher prevalence of cardiovascular comorbidities, and experienced more severe strokes (median National Institutes of Health Stroke Scale score, 10 [IQR, 5 to 17] vs 7 [IQR, 4 to 14]) (all standardized differences >10). The unadjusted rate of symptomatic intracranial hemorrhage was 3.7% (95% CI, 2.9% to 4.5%) for patients taking NOACs vs 3.2% (95% CI, 3.1% to 3.3%) for patients not taking anticoagulants. After adjusting for baseline clinical factors, the risk of symptomatic intracranial hemorrhage was not significantly different between groups (adjusted odds ratio [OR], 0.88 [95% CI, 0.70 to 1.10]; adjusted risk difference [RD], -0.51% [95% CI, -1.36% to 0.34%]). There were no significant differences in the secondary safety outcomes, including inpatient mortality (6.3% for patients taking NOACs vs 4.9% for patients not taking anticoagulants; adjusted OR, 0.84 [95% CI, 0.69 to 1.01]; adjusted RD, -1.20% [95% CI, -2.39% to -0%]). Of the secondary functional outcomes, 4 of 7 showed significant differences in favor of the NOAC group after adjustment, including the proportion of patients discharged home (45.9% vs 53.6% for patients not taking anticoagulants; adjusted OR, 1.17 [95% CI, 1.06 to 1.29]; adjusted RD, 3.84% [95% CI, 1.46% to 6.22%]).

CONCLUSIONS AND RELEVANCE: Among patients with acute ischemic stroke treated with intravenous alteplase, use of NOACs within the preceding 7 days, compared with no use of anticoagulants, was not associated with a significantly increased risk of intracranial hemorrhage.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Kam W, Holmes DN, Hernandez AF, et al. Association of Recent Use of Non-Vitamin K Antagonist Oral Anticoagulants With Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Treated With Alteplase. JAMA. 2022. PMID: 35143601. doi:10.1001/jama.2022.0948

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。